A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.

TL;DR

CLINICAL BREAKDOWN

At some point in her late 40s, a woman describes to her doctor something she cannot fully explain. She has not changed what she eats or how much she exercises. But something is different.

She feels weaker. Her body composition has shifted. Something structural feels off.

The response, almost always, is a conversation about estrogen.

That is not particularly inaccurate, but estrogen is not the whole story. And for the specific changes she is describing, it may not even be the primary factor.

Estrogen collapses fast. It drops by as much as 80 percent across the menopausal transition, and the effects are immediate and unmistakable. Testosterone takes part in a process that is much slower, and that peaks in your early twenties. Then it declines by roughly half before you reach 40. By the time the final menstrual period arrives, testosterone has already been falling for nearly two decades.

This reframe matters. If the working assumption is that menopause depletes testosterone, the intervention window looks like it starts at or after the final period.

If the working assumption is that testosterone has been declining since your mid-20s and the ovarian transition compounds an existing deficit, the conversation starts much earlier. And the evidence supports the second frame.

Here is what that means in practice. By the time a woman is around 45 and begins noticing perimenopausal symptoms, she may already be operating with half the testosterone she had at her peak.

The decline is not menopause arriving. It is two decades of gradual loss reaching the point where it becomes noticeable.

The Study of Women's Health Across the Nation tracked over 3,000 women across the menopausal transition using statistical models built specifically to separate what aging does from what the transition itself does. The results are specific enough to be useful.

Lean mass. Muscle declines gradually with chronological age. But there is a transition-specific acceleration.

Loss picks up from about two years before the final menstrual period to roughly a year and a half after it. The rate during that window is faster than what age alone explains. When that window closes, the rate slows.

Greendale GA et al., JCI Insight, 2019.

Bone density. The spine and hips lose approximately 2.5 percent annually during a three-to-four-year window centered on the final menstrual period. Before that window, bone loss is slow. After that, bone loss slows again.

Osteoporotic fractures do not develop gradually over a lifetime. They develop from a short period of rapid loss that most women are never told about.

Greendale GA et al., J Bone Miner Res, 2012.

LDL and ApoB both increase by an average of 10 to 12 milligrams per deciliter within the one year around the final menstrual period.

Then the acceleration stops. This is not a slow cardiovascular drift. It is a discrete, hormone-driven event.

El Khoudary SR et al., Circulation, 2020.

The pattern is similar in every system. The transition is the accelerant. Aging is just background.

This distinction matters clinically. If these changes were simply aging, interventions would need to work across decades. Because they are transition-specific, there is a window. Know when the window opens.

Testosterone is described, still, as a male hormone. The research does not support that framing.

The levator ani is the sling of muscle and connective tissue holding the bladder, uterus, and rectum in position. Human biopsy studies show androgen receptors throughout its striated muscle fibers and in the stromal connective tissue.

Copas P et al., J Womens Health Gend Based Med, 2001.

This matters because testosterone is the ligand those receptors are waiting for. Whether the signal actually arrives in a useful concentration, and whether it drives meaningful muscle growth in this specific tissue, is the question medicine has not yet answered.

The frequently repeated claim that this muscle is the most androgen-sensitive tissue in the body deserves a footnote. That claim originates from rodent bioassay work, not from human data.

In rats, the levator ani is a tail manipulator and copulatory structure fused with the genitals. It is built almost entirely from fast-twitch fibers and responds dramatically to androgens in lab assays.

The human pelvic floor is built differently: roughly 70 percent slow-twitch fibers, designed for constant tonic contraction under gravity.

The receptor density in humans is real. The extreme androgen sensitivity is a rodent finding that has traveled further than its evidence supports.

Researchers at Brigham and Women's Hospital ran the most direct human test of testosterone's anabolic effect in women. In 71 hysterectomized women with low testosterone, participants received escalating weekly doses over 24 weeks.

The results on systemic muscle were unambiguous.

Lean mass increased by roughly 1.5 kilograms per 100-point rise in serum testosterone. Chest press power increased by 25 watts at the highest dose. Stair climbing power increased by 48 watts.

Huang G, Basaria S et al., Menopause, 2014.

Then they asked the next question. They pulled 24 of those women into MRI scanning to look specifically at the pelvic floor.

The paraspinal muscles grew. The psoas grew. The abdominal wall grew. The pelvic floor showed no measurable change.

Tapper J, Huang G et al., Menopause, 2019.

This null result is probably a measurement problem, not a biological one. Twenty-four patients is underpowered. A 1.5 Tesla MRI scanner lacks the spatial resolution to detect small changes in a muscle that is often two to four millimeters thick.

The result was null. Reporting it as anything else would be inaccurate.

Two trials at Brigham are running the proper test right now: high-resolution imaging, urodynamic testing, more patients. Until those read out, the honest position is this: testosterone builds muscle in women throughout the body.

Whether that effect reaches the pelvic floor specifically has not been demonstrated in a published human trial.

Current trials: NCT04026880 and NCT06111209 (Brigham and Women's Hospital, enrolling)

The frontier is real. The evidence is not there yet.

ONE ACTIONABLE PROTOCOL

The testosterone question is open. The science is in motion and the trials are not complete. These three are not in question.

READER PULSE

The evidence on testosterone for pelvic floor health is live, not settled. Trials are enrolling now.

Published for educational purposes. Not a substitute for professional medical advice. Evidence tiers indicate study type, not clinical endorsement.